Verrica Pharmaceuticals vs Zentalis Pharmaceuticals
VRCA and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VRCA and ZNTL compare
Zentalis Pharmaceuticals is the larger company, worth 2.1 times as much as Verrica Pharmaceuticals ($115M against $55.0M).
Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VRCA | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | $55.0M | $115M |
| Share price | $3.20 | $1.60 |
| Change, 1 year | −17.3% | 21.2% |
| Change, 5 years | −96.9% | −97.9% |
| Beta (5Y) | 5.05 | 5.70 |
| Employees | 76 | 106 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× | – |
| P/B | 12.8× | 0.8× (better) |
| FCF yield | – | −112% |
| Growth | ||
| Revenue growth (TTM) | 106% | – |
| Profitability | ||
| Operating margin | −93.6% | – |
| Net margin | −103% | – |
| Return on equity | – | −66.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −7.6× | – |
| Current ratio | 1.45 | 4.82 (better) |
| Altman Z-score | −13.90 | −8.84 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 27.1% | 66.1% |
| Held by insiders | – | 58.0% |
| Insider net buying, 12 months | $211K | $12.8M (better) |
| Short interest, % of float | – | 16.7% |
Go deeper
- VRCA stock overview
- VRCA income statement
- VRCA valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.